AZ’s latest purchase fails to impress investors
April 25, 2007Sales and Marketing
AstraZeneca has entered the lucrative vaccine market and gained a range of potential new biologic products with the £15.6 billion …
Clinical trial news from Datamonitor
April 18, 2007Research and Development
Array BioPharma receives payment for cancer inhibitorArray BioPharma has received a $2 million milestone payment from AstraZeneca after its MEK …
Product news roundup from Datamonitor
April 18, 2007Sales and Marketing
Changing of the guard in HIV treatmentThe HIV market is forecast to grow from $7.1 billion in 2005 to an …
Lilly upbeat after strong start to year
April 18, 2007Sales and Marketing
Stronger than expected sales and profits in early 2007 has lifted Lilly, prompting the US pharma company to raise its …
Public to get clearer picture of hospital bugs
April 18, 2007NHS
The government is to turn up the heat on trusts over rising levels of hospital infections by showing the public …
Diabetes drug costs double in five years
April 18, 2007Sales and Marketing
A growing number of patients and a switch to newer medicines has brought about a doubling of England's spending on …
Athena wins two Pfizer accounts
April 18, 2007Medical Communications
Athena Medical PR has been appointed by Pfizer UK to run its PR campaigns for two of its anti-infective products: …
Europe’s buoyant biotech set for further growth
April 16, 2007Research and Development, Sales and Marketing biotech
A new comprehensive survey of the world's biotechnology industry shows the sector to be in great health, with indications of …
NICE in the dock: what the judicial review means for pharma
April 16, 2007Research and Development, Sales and Marketing NICE, UK, healthcare, judicial review
The National Institute for Health and Clinical Excellence (NICE) has been at the centre of controversy ever since its inception …
Product news from Datamonitor
April 16, 2007Research and Development, Sales and Marketing
Carrington Laboratories to manufacture sublingual vaccinesCarrington Laboratories has reported that its subsidiary DelSite Biotechnologies has entered into an agreement with …
Company news from Datamonitor
April 16, 2007Sales and Marketing
Avenir plans restructure and ends AZ collaborationsAvanir Pharmaceuticals has said it plans to implement a restructuring plan and has ended …
NHS will be ‘unrecognisable’ in 10 years’ time, say doctors
April 16, 2007NHS
Most young doctors believe the NHS will be unrecognisable in 10 years' time, a new survey has revealed.The research, published …
Europe imposes restrictions on Ketek prescribing
April 16, 2007Sales and Marketing Ketek, safety
The European Medicines Agency has issued guidance for the four indications of Ketek, the Sanofi-Aventis antibiotic stripped of several indications …
Encouraging New Thinking in Strategic Planning
April 12, 2007Sales and Marketing marketing, planning, strategic planning, strategy
How many pharma marketers, faced with the annual chore of writing a strategic plan, have decided not to take the …
Product Development Update
April 12, 2007Research and Development, Sales and Marketing
Product news round-up from Datamonitor ChemGenex begins CML trialChemGenex Pharmaceutical has treated the first patient in a new phase II/III clinical …
Change in US law could cut drugs spending by $30 billion
April 12, 2007Sales and Marketing US, reform
Calls to allow the US government to negotiate drug prices with the pharmaceutical industry have been reawakened by a new …
Abbott lowers prices on HIV drugs
April 12, 2007Sales and Marketing HIV, par
Intervention from the World Health Organisation has spurred Abbott to lower its prices on HIV drugs in developing countries.The company …
Resolute to open New York office
April 12, 2007Medical Communications Resolute
London-based healthcare consultancy Resolute is to break into the all-important US market by opening an office in New York.Resolute was …
Sales representatives blow the whistle on rule-breaking call rates
April 11, 2007Sales and Marketing ABPI, ethics
Pharmaceutical sales representatives are turning to the industry regulator and blowing the whistle on their own companies, when they are …
Novartis’ Zelnorm pulled from market after safety concerns
April 2, 2007Sales and Marketing FDA, reg
Zelnorm, the treatment for irritable bowel syndrome, has been withdrawn from the US market after the FDA raised concerns about …
Latest content
FibroFind appoints Lee Borthwick as CEO
